Annual Reports

View our annual report 2024

Financial

CSL financial

Delivering a step change in commercial execution with growth across the portfolio.

A strong year with NPATA attributable to equity holders of US$2.91 billion for the year ended 30 June 2024, up 11% on a reported currency basis when compared to the prior comparable period.
Strong growth in Immunoglobulins portfolio, up 20% at constant currency.
CSL Seqirus revenue up 4% at constant currency driven by strong growth in FLUAD^®.
CSL Vifor well positioned for an evolving iron market.

Operational

CSL Operational

Supporting growth in operating profit and earning per share (EPS).

Record levels of plasma collections.
110 million influenza vaccine doses distributed by CSL Seqirus.
Base fractionation capacity completed at Broadmeadows and Marburg.
Participated in 479 regulatory inspections of our manufacturing facilities and plasma collection centres.
Vifor cost synergies delivered ahead of expectation.
Rika rollout in 84 centers as at 30 June 2024, and on track for completion by the end of FY2025.

Research and Development

CSL research

Focused on innovative products, innovative manufacturing processes and protecting the health of patients and the general public.

To ensure a robust and diverse innovation pipeline based on a foundation of scientific excellence, CSL continues to strengthen its therapeutic area focus underpinned with robust technical development platforms.
HEMGENIX^®, the first FDA-approved gene therapy for adults with haemophilia B, won Best Product for Rare/Orphan Diseases at the 2023 Prix Galien USA Award.

Sustainability

CSL sustainability

Evolving our sustainability strategy, creating a foundation for success and shared value creation through 2030 and beyond.

Set new initial goals in support of performance across CSL’s sustainability focus areas that seek to enable a healthier world, also embedding health equity and empowerment and inclusion and belonging as part of CSL’s strategic focus areas.
Ranked among the best large employers in America by Forbes magazine and named to Forbes Global 2000; also among Work180 Top Workplaces for Women in Australia and Prosple Top 100 Graduate Employers in Australia.
Continue to advance best-in-class plasma donor experience with the rollout of the Rika Plasma Donation System™, Project REACH and individualised nomograms.

* Limited assurance by Ernst & Young.

¹ Constant currency (CC) removes the impact of exchange rate movements, facilitating the comparability of operational performance. For further detail refer to CSL’s Financial Statements for the Full Year ended June 2023 (Directors Report).

This browser is no longer supported

Annual Reports

Financial

Operational

Research and Development

Sustainability

Annual Report Archive

Introduction to CSL

Board and Management

Corporate Governance